Feedback on proposal to amend access criteria for type 2 diabetes medicines
Overview
We're seeking your feedback on a proposal for people living with Type 2 diabetes and at risk of cardio-renal complications. We are proposing to widen access to:
- empagliflozin (Jardiance)
- empagliflozin with metformin (Jardiamet)
- dulaglutide (Trulicity)
- liraglutide (Victoza)
Audiences
- Advice and Assessment Directorate
- Corporate Directorate
- Equity and Engagement Directorate
- Family/whānau of someone who uses medicines
- Friend of someone who uses medicines
- Medical Devices Directorate
- Office of the CE
- Other health care professionals
- Other member of the public
- Person who uses medicine
- Pharmaceutical Directorate
- Pharmacists
- Prescribers
- Representative of a consumer group
- Strategy, Policy and Performance Directorate
- Supplier
- Wholesaler
Share
Share on Twitter Share on Facebook